Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial-Reference-Cited by-同舟云学术

Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial

Published:2006-08-17 Issue:10 Volume:20 Page:1723-1730
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Jehn U,Suciu S,Thomas X,Lefrère F,Muus P,Berneman Z,Marie J-P,Adamo F,Fillet G,Nobile F,Ricciuti F,Leone G,Rizzoli V,Montanaro M,Beeldens F,Fazi P,Mandelli F,Willemze R,de Witte T,Amadori S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404356.pdf

Reference22 articles.

1. Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13: 843–849.

2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. For the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217–223.

3. Cassileth PA, Harrington DP, Appelbaum F, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 198; 339: 1649–1656.

4. Burnett AK, Goldstone AH, Stevens R, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.

5. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy – the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukaemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872–881.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia;Cancer Medicine;2021-03-30

2. Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials;Cancers;2020-11-11

3. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients;Scientific Reports;2017-09-12

4. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia;Leukemia Research;2014-04

5. Acute myeloid leukemia in the elderly;International Journal of Hematologic Oncology;2012-10